Lentiviral Vector CDMOs — Ranked by Signal Score · 2026
Lentiviral Vector manufacturers on CDMO Signal: 34 listed. 6 are fully evidenced (all four Signal Score pillars and at least one ClinicalTrials.gov match). The highest Signal Scores in that fully evidenced set are AGC Biologics (Signal Score 79.9), Thermo Fisher Scientific (Signal Score 77.6) and Oxford Biomedica (also makes its own products, Signal Score 76.2). Outside that set, higher Signal Scores on this list include Pharmaron (Signal Score 86.9), Charles River Laboratories (Signal Score 86.3) and ReciBioPharm (Signal Score 82.9). A higher score there is not a fully evidenced record. The score does not measure BSL-2 containment, suspension scale, or potency and replication-competent lentivirus testing. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.
Lentiviral CDMOs with the most regulatory evidence on file
Shortlist lentiviral vector CDMOs with Signal
CDMO Signal is an independent sourcing platform CAR-T, TCR, and ex vivo gene therapy sponsors use to compare and shortlist lentiviral vector CDMOs before an RFI. This page is the entry point — the ranked table below is derived from FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor and program footprint, and monitored capacity signals. Use it to narrow the field, then verify BSL-2, RCL, potency, and scale directly with the shortlisted suppliers.
- Compare lentiviral vector CDMOs side-by-side on FDA inspection history, EMA/MHRA GMP certificate density, ClinicalTrials.gov sponsor and program footprint, and monitored capacity signals — every number traceable to primary sources.
- Filter by regulatory jurisdiction, clean-inspection posture, and clinical-program breadth to your CAR-T, TCR, or ex vivo gene therapy program's shortlisting criteria.
- Shortlist Use the ranked results to build your shortlist, then open each profile to review the underlying evidence before contacting suppliers. Follow up with the shortlisted CDMOs to verify BSL-2 containment, RCL testing, potency, and scale directly.
Lentiviral vectors are the workhorse of ex vivo gene therapy — used to engineer T cells for CAR-T, TCR programs, and to modify hematopoietic stem cells for inherited disorders. Because the vector integrates into the genome of patient-bound cells, lentiviral manufacturing carries the regulatory weight of a critical starting material under full GMP, mandatory replication-competent lentivirus (RCL) testing, and BSL-2 containment throughout production.
Selecting a lentiviral vector CDMO comes down to five buyer-critical dimensions: BSL-2 containment maturity and site inspection history on lentivirus specifically, a scalable suspension (or well-run adherent) platform, qualified titer + potency + RCL assays, capacity headroom at your target dose × patient volume, and defensible tech-transfer support. The rankings below score each CDMO on FDA inspection classifications, EMA/MHRA GMP density, ClinicalTrials.gov sponsor breadth, and monitored capacity signals — a composite that reflects the regulatory record and operational depth needed for material that lands in patient-bound cells.
FDA inspection outcomes across these CDMOs: 24 NAI (no action), 38 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (43), UNITED KINGDOM (38), Denmark (23), Germany (10), United Kingdom (7).
Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing all operator types.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
PB
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 5 insp · 1 GMP | 2026-08-14 · NAI | Available | — |
| 2 |
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
|
86.3 | 99.2 | 9 insp · 11 GMP | 2026-05-01 · NAI | Limited | — |
| 3 |
RP
Keele, UK · Sodertalje, SE
|
82.9 | 100.0 | 0 insp · 3 GMP | None on file | — | — |
| 4 |
BR
|
80.3 | 97.2 | 6 insp · 10 GMP | 2026-05-13 · VAI | — | — |
| 5 |
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
|
79.9 | 99.8 | 4 insp · 27 GMP | 2026-05-29 · NAI | Available | 2 programs |
| 6 |
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
|
79.5 | 100.0 | — | None on file | Available | — |
| 7 |
BV
|
79.4 | 99.8 | 1 insp · 4 GMP | 2024-12-19 · VAI | — | — |
| 8 |
GZ
|
78.1 | 100.0 | 1 insp · 0 GMP | 2025-08-27 · NAI | Available | — |
| 9 |
AA
Rockville, MD · Alachua, FL · Munich, DE
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 10 |
NG
Leiden, NL
|
78.1 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 11 |
ET
Jumet, BE
|
78.1 | 100.0 | 0 insp · 4 GMP | None on file | — | — |
| 12 |
PG
Berlin, DE
|
78.1 | 100.0 | 0 insp · 4 GMP | None on file | — | — |
| 13 |
AD
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 2 GMP | None on file | — | — |
| 14 |
TF
Plainville, MA · Alachua, FL · Cambridge, MA
Hiring · 299 open roles
Fully evidenced
|
77.6 | 93.2 | 19 insp · 10 GMP | 2026-06-30 · NAI | Available | 2 programs |
| 15 |
AG2
San Carlos, CA
|
77.6 | 98.8 | 1 insp · 0 GMP | 2025-04-18 · VAI | — | — |
| 16 |
OX
Oxford, United Kingdom
Hiring · 4 open roles
Fully evidenced
Also makes its own products
|
76.2 | 100.0 | 2 insp · 13 GMP | 2024-06-17 · NAI | Available | 7 programs |
| 17 |
CI
Cincinnati, OH
Hiring · 2 open roles
Fully evidenced
Academic / national centre
|
75.1 | 99.6 | 2 insp · 0 GMP | 2025-02-05 · NAI | — | 1 program |
| 18 |
NR
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Hiring · 100+ open roles
Fully evidenced
|
73.6 | 95.6 | 1 insp · 0 GMP | 2025-01-21 · VAI | Available | 9 programs |
| 19 |
|
72.8 | 86.6 | 11 insp · 8 GMP | 2025-09-29 · VAI | — | 1 program |
| 20 |
BB
|
70.5 | — | — | None on file | — | — |
| 21 |
IU
|
66.3 | — | — | None on file | — | 49 programs |
| 22 |
VE
Rockville, MD · Memphis, TN · Keele, United Kingdom
|
64.0 | — | — | None on file | — | — |
| 23 |
AN
Columbus, OH
|
63.0 | — | — | None on file | Available | — |
| 24 |
RA
Stockholm, Sweden
|
63.0 | — | — | None on file | — | — |
| 25 |
OB
Hamilton, ON
|
61.5 | — | 0 insp · 2 GMP | None on file | — | — |
| 26 |
GF
Alameda, CA and South San Francisco
|
61.5 | — | — | None on file | Available | — |
| 27 |
MA
College Station, TX
|
59.0 | — | — | None on file | Available | — |
| 28 |
VB
Philadelphia, PA
|
59.0 | — | — | None on file | — | — |
| 29 |
WB
Madison, WI
|
59.0 | — | — | None on file | — | — |
| 30 |
EB
|
59.0 | — | — | None on file | — | — |
| 31 |
VM
Cambridge, MA
|
59.0 | — | — | None on file | — | — |
| 32 |
AM
Gerenzano, Italy
|
59.0 | — | — | None on file | — | — |
| 33 |
TR
Kusatsu, Shiga Prefecture, Japan
|
57.9 | — | — | None on file | — | 8 programs |
| 34 |
UB
|
56.5 | — | — | None on file | — | — |